Asia Deal Watch: MEI Partners ME-401 With Japan’s Kyowa Hakko Kirin, Following Chinese Deal With BeiGene
Executive Summary
About a month after signing a development and commercialization partnership in China for its PI3K delta inhibitor, MEI signs a deal for Japanese rights to the compound with Kyowa Hakko Kirin. Cue and LG Chem partner to develop targeted T-cell therapies for cancer.
You may also be interested in...
Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Cipla Acquires Avenue, Primes Play In Pain Amid US Opioid Crisis
Cipla has struck a 'de-risked' deal to acquire the specialty firm Avenue Therapeutics, Inc, for up to $215m as it readies a niche play in the US pain management segment amid the opioid crisis.
Big Statement By Aurobindo As It Seals $1bn Sandoz US Deal
Aurobindo is betting big, buying certain portions of Sandoz’s US portfolio in a deal potentially worth $1bn. The acquisition positions the Indian firm in the top league in the overall US generics space by Rx and also segments like dermatology, but much could depend on how effectively Aurobindo delivers on value creation potential amid ongoing price pressures.